作者:Mark W. Ledeboer、Albert C. Pierce、John P. Duffy、Huai Gao、David Messersmith、Francesco G. Salituro、Suganthini Nanthakumar、Jon Come、Harmon J. Zuccola、Lora Swenson、Dina Shlyakter、Sudipta Mahajan、Thomas Hoock、Bin Fan、Wan-Jung Tsai、Elaine Kolaczkowski、Scott Carrier、James K. Hogan、Richard Zessis、S. Pazhanisamy、Youssef L. Bennani
DOI:10.1016/j.bmcl.2009.10.053
日期:2009.12
Constitutive activation of the EPO/JAK2 signaling cascade has recently been implicated in a variety of myeloproliferative disorders including polycythemia vera, essential thrombocythemia and myelofibrosis. In an effort to uncover therapeutic potential of blocking the EPO/JAK2 signaling cascade, we sought to discover selective inhibitors that block the kinase activity of JAK2. Herein, we describe the discovery and structure based optimization of a novel series of 2-amino-pyrazolo[1,5-a]pyrimidines that exhibit potent inhibition of JAK2. (C) 2009 Elsevier Ltd. All rights reserved.